High and rising prescription drug prices force consumers to skip doses or even avoid filling their prescriptions for life-saving medications altogether. Now is the perfect time for Congress to finally begin to take action by passing the bipartisan CREATES Act.
In this June 12, 2019 testimony before the U.S. House of Representatives Energy and Commerce Subcommittee on Health, Claire McAndrew, Director of Campaigns and Partnerships at Families USA, breaks down the problem with surprise medical bills and potential solutions under consideration by the committee.
This brief summarizes 2019 state legislative activity on surprise medical bills.
This guide outlines model policies for states to consider to rein in drug prices in 2019 and beyond. Those discussed first most directly target drug prices and therefore are likely to have the greatest impact. This piece also cautions against prioritizing approaches to import drugs from Canada, as these policies are less likely to bring savings despite their public appeal.
Congressional committees have advanced initial measures to address prescription drug costs. However, their work to date has not focused on the significant policy changes needed to meaningfully lower drug prices. To address the drivers of excessive prescription drug prices in the United States, the Coalition for Fair Drug Prices urges Congress to enact meaningful policies that leverage the federal government’s power to negotiate drug prices.
Families USA submitted the attached letter to U.S. House of Representatives Leadership in support of H.R. 987, the Strengthening Health Care and Lowering Prescription Drug Costs Act.
Drug companies consistently set high prices, which forces families to make impossible choices between their health care and other basic needs. Drug companies set exorbitant prices by design to maximize their profits, while making misleading claims that high prices simply fund innovative new drugs. Despite this gaming, our political system makes it easy for drug companies to continue exploitative pricing. This piece explains how our current drug pricing system leads to unaffordable prescription drugs, and ultimately harms people’s health.
Health and Health Care in 2019 Legislative Sessions: States Step Up on Public Options, Coverage, Drug Pricing, and More
In this testimony before the U.S. House of Representatives Energy and Commerce Committee on May 21, 2019, Frederick Isasi, Executive Director of Families USA, breaks down the problem with high drug prices and potential solutions under consideration by the committee. While high drug prices are a source of seemingly constant debate in Washington, D.C., for millions of America’s families, they are a painful and burdensome reality and can impact the basic necessities of life.
Families USA, in partnership with American Academy of Family Physicians, American Benefits Council, American Federation of State, Country, and Municipal Employees, American Federation of Teachers, First Focus, and Pacific Business Group on Health, is launching Consumers First: The Alliance to Make the Health Care System Work for Everyone.